Daniel Kramer is a Cardiology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
185 Pilgrim Rd
Boston, MA 022155324
Telephone
617-667-8800Registry record last updated 25 Feb 2016.
Clinical trials
- TRAjectories and CLinical ExpeRiences of ICD Therapy Study
Sponsor: Beth Israel Deaconess Medical Center
- Safety and Clinical Outcomes of Magnetic Resonance Imaging in Patients With Cardiac Implantable Electrical Devices
Sponsor: Beth Israel Deaconess Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Biosense Webster, Inc.Program year202522 payments$58,342openpaymentsdata.cms.gov ↗
- Biosense Webster, Inc.Program year202416 payments$184,590openpaymentsdata.cms.gov ↗
- Abbott LaboratoriesProgram year202417 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
100%Beta blocker100%Metoprolol Succinate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2013–2025 per NIH RePORTER. The latest:
- Prospective Investigation of Palliative and End-of-Life ExpeRiences with ICDs (PIPER-ICD) Study
Beth Israel Deaconess Medical Center
FY2025$722,855R01HL161697 - The Trajectories and Clinical Experiences of ICD Therapy (TRACER-ICD) Study
Beth Israel Deaconess Medical Center
FY2025$606,499R01AG068141 - Prospective Investigation of Palliative and End-of-Life ExpeRiences with ICDs (PIPER-ICD) Study
Beth Israel Deaconess Medical Center
FY2024$710,090R01HL161697
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”